Novo Nordisk has downplayed the severity of gastrointestinal problems caused by Ozempic, according to lawsuit filed by a user left with gastroparesis, also known as a paralyzed stomach.
Amid rising concerns about the widespread use of Ozempic, European investigators are expanding an investigation into potential suicide side effects associated with new diabetes and weight loss drugs.
Attorneys are investigating more than 10,000 potential Ozempic, Wegovy and Mounjaro lawsuits that may soon be filed on behalf of users who experienced stomach paralysis injuries.
A South Dakota man has filed one of the first gastroparesis lawsuits against Ozempic manufacturers, alleging that users have not been adequately warned about the risk of severe vomiting and long-term stomach side effects.
The findings are likely to further increase the use of Wegovy, Ozempic and similar drugs, despite growing concerns about severe stomach problems experienced by some users.
In response to a failure to warn lawsuit brought by a Louisiana woman who developed painful stomach paralysis, the manufacturer claims Ozempic gastrointestinal side effects were well disclosed to doctors and consumers
Approval comes amid growing reports of stomach paralysis from Mounjaro, Ozempic and similar drugs, which have led to a number of lawsuits over failure to warn about the potential side effects
Plaintiff was hospitalized due to Ozempic gastroparesis, which led to a gastrointestinal blockage, chronic diarrhea, heartburn, pain and hospitalization.
The cost of Ozempic, Wegovy and other similar diet drugs often exceeded most people's "willingness-to-pay" price point for the weight loss benefits they provided, researchers noted.
At only 17, Plaintiff was inserted with a feeding tube due to stomach paralysis caused by the HPV vaccine administered to prevent cervical cancer.
